[Monitoring sodium valproate treatment of epilepsy in the development years]
Neurologia I Neurochirurgia Polska
|January 1, 1987
Insights
Saliva tests can monitor sodium valproate levels in children with epilepsy, offering a simple alternative to blood draws. This method helps ensure systematic drug intake and approximate serum levels for effective treatment.
Area of Science:
- Pharmacology
- Clinical Chemistry
- Pediatric Neurology
Context:
- Epilepsy management in children requires consistent medication adherence.
- Monitoring therapeutic drug levels is crucial for treatment efficacy and safety.
- Traditional blood sampling for drug level monitoring can be invasive and burdensome for pediatric patients.
Purpose:
- To evaluate the utility of salivary sodium valproate measurements as a non-invasive method for therapeutic drug monitoring in children.
- To correlate salivary drug concentrations with serum levels of sodium valproate.
- To assess the feasibility of using saliva tests for routine monitoring of medication adherence in pediatric epilepsy patients.
Summary:
- Sodium valproate levels were measured in both blood and saliva samples from children undergoing epilepsy treatment.
- Saliva drug determination was found to be a simple method to verify systematic medication intake.
- This approach allows for the estimation of approximate serum drug levels without the need for blood sampling, simplifying patient management.
Impact:
- Salivary monitoring offers a patient-friendly alternative for assessing medication adherence and therapeutic drug levels in pediatric epilepsy.
- This non-invasive method can improve compliance and potentially lead to better seizure control by ensuring consistent drug exposure.
- In cases of poor treatment response, serial monitoring of valproic acid via saliva can aid in clinical decision-making and treatment adjustments.
Abstract:
The levels of sodium valproate were determined in the blood and saliva of children treated for epilepsy. The determination of drug in saliva may be a simple test checking whether the patient is taking the drugs systematically, and makes possible determination of the approximate level in the serum without blood sampling. In doubtful cases poorly responding to treatment serial monitoring of valproic acid should be undertaken.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...